Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031967 · ClinicalTrials.gov registry record · Phase 2
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00031967 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group.
The verdict
NCT00031967, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy. PURPOSE: Randomized phase II trial to determine the effectiveness of combining melatonin with radiation therapy in treating patients who have brain metastases.
Interventions
- RADIATION radiation therapy
- DRUG therapeutic melatonin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031967
The ClinicalTrials.gov registry entry for NCT00031967 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00031967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031967 about?
NCT00031967 is a clinical study titled "Melatonin and Radiation Therapy in Treating Patients With Brain Metastases". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy. PURPOSE: Randomized phase II trial to determine the effectiveness of ...
What is the current status of trial NCT00031967?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-05.
What interventions are being tested in trial NCT00031967?
The interventions under investigation include: radiation therapy (RADIATION), therapeutic melatonin (DRUG).
Who is sponsoring clinical trial NCT00031967?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.